Chardan Capital Issues Optimistic Forecast for COYA Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Equities researchers at Chardan Capital lifted their FY2025 earnings per share estimates for shares of Coya Therapeutics in a report issued on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the company will earn ($1.03) per share for the year, up from their prior estimate of ($1.26). Chardan Capital has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share.

Separately, D. Boral Capital restated a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Thursday.

Coya Therapeutics Trading Down 4.8 %

Shares of NASDAQ COYA opened at $6.56 on Thursday. The stock has a market cap of $109.72 million, a price-to-earnings ratio of -10.09 and a beta of 0.31. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.24. The stock’s 50-day moving average is $6.43 and its 200 day moving average is $6.51.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. The business had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.10 million.

Institutional Trading of Coya Therapeutics

Several institutional investors have recently bought and sold shares of COYA. Tower Research Capital LLC TRC raised its stake in shares of Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after purchasing an additional 4,777 shares during the last quarter. XTX Topco Ltd purchased a new position in Coya Therapeutics in the 4th quarter worth about $59,000. Jane Street Group LLC bought a new position in Coya Therapeutics during the 4th quarter valued at about $74,000. Northern Trust Corp boosted its holdings in shares of Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock valued at $164,000 after acquiring an additional 3,099 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. bought a new stake in shares of Coya Therapeutics in the fourth quarter worth approximately $401,000. 39.75% of the stock is owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.